The Landscape and Therapeutic Targeting of BRCA1, BRCA2 and Other DNA Damage Response Genes in Pancreatic Cancer

• Published in: Current issues in molecular biology Vol. 45; no. 3; pp. 2105 - 2120
• Main Authors: Voutsadakis, Ioannis A., Digklia, Antonia
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI 03.03.2023; MDPI AG
• Subjects: ATR inhibitors; DNA damage response; homologous recombination; pancreatic adenocarcinoma; PARP; Review; pancreatic adenocarcinoma; PARP; homologous recombination; DNA damage response; ATR inhibitors
• ISSN: 1467-3045; 1467-3037; 1467-3045
• DOI: 10.3390/cimb45030135

Genes participating in the cellular response to damaged DNA have an important function to protect genetic information from alterations due to extrinsic and intrinsic cellular insults. In cancer cells, alterations in these genes are a source of genetic instability, which is advantageous for cancer progression by providing background for adaptation to adverse environments and attack by the immune system. Mutations in BRCA1 and BRCA2 genes have been known for decades to predispose to familial breast and ovarian cancers, and, more recently, prostate and pancreatic cancers have been added to the constellation of cancers that show increased prevalence in these families. Cancers associated with these genetic syndromes are currently treated with PARP inhibitors based on the exquisite sensitivity of cells lacking BRCA1 or BRCA2 function to inhibition of the PARP enzyme. In contrast, the sensitivity of pancreatic cancers with somatic BRCA1 and BRCA2 mutations and with mutations in other homologous recombination (HR) repair genes to PARP inhibitors is less established and the subject of ongoing investigations. This paper reviews the prevalence of pancreatic cancers with HR gene defects and treatment of pancreatic cancer patients with defects in HR with PARP inhibitors and other drugs in development that target these molecular defects.